Genelabs Technologies Email Format

Biotechnology ResearchUnited States11-50 Employees

Genelabs Technologies is a biotechnology research company based in the United States focused on discovering and developing novel compounds to treat infectious diseases. Its work centers on advancing therapies that can selectively inhibit replication of hepatitis C virus by targeting its viral proteins, while also pursuing a late-stage drug candidate for hepatitis E through a partnership with GlaxoSmithKline. The company engages in both partnered and proprietary programs, aiming to address unmet needs in viral infectious disease treatment. Since its acquisition by GlaxoSmithKline in January 2009, its collaboration activity reflects an emphasis on leveraging external partnerships to progress its research portfolio.

Sign up for free to view info

Company overview Employee directory